Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies
Bernhard J. Steinhoff, Elinor Ben-Menachem, Philippe Ryvlin, Simon Shorvon, Lynn Kramer, Andrew Satlin, David Squillacote, Haichen Yang, Jin Zhu, Antonio Laurenza
Abstract
Three phase III studies (304 [ClinicalTrials.gov identifier: NCT00699972], 305 [NCT00699582], 306 [NCT00700310]) evaluated perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor antagonist, as adjunctive therapy for refractory partial seizures. We report post hoc analyses of pooled study data by randomized dose.